zardaverine has been researched along with Carcinoma, Squamous Cell in 1 studies
zardaverine: structure given in first source
zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fryknäs, M | 1 |
| Rickardson, L | 1 |
| Wickström, M | 1 |
| Dhar, S | 1 |
| Lövborg, H | 1 |
| Gullbo, J | 1 |
| Nygren, P | 1 |
| Gustafsson, MG | 1 |
| Isaksson, A | 1 |
| Larsson, R | 1 |
1 other study available for zardaverine and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
Topics: Carcinoma, Squamous Cell; Caspases; Combinatorial Chemistry Techniques; Drug Evaluation, Preclinical | 2006 |